Ad
Thursday, 7 September 2017
FDA widens holds on immunotherapy combination blood cancer trials
(Reuters) - U.S. health regulators stopped five blood cancer trials testing AstraZeneca Plc's immunotherapy Imfinzi in combination with Celgene Corp medicines from accepting new patients and halted another study entirely, the companies said on Thursday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment